Intendis Inc. is a U.S. based affiliate of Intendis GmbH, a fully integrated pharmaceutical company based in Berlin, Germany. As part of Bayer HealthCare, Intendis is completely dedicated to Dermatology and focuses on the development and marketing of high quality, innovative topical therapies, targeted to treat skin disorders. Intendis recognizes the important role of Physician Assistants in the field of dermatology, and is pleased to support the SDPA, with the objective of becoming a leading partner in the field of dermatology. Find out more at www.intendis.com.

To access the Intendis video library, click here.

FINACEA® (azelaic acid) Gel, 15%

FINACEA is the first prescription gel approved by the FDA for the treatment of lesions and erythema of mild to moderate rosacea. FINACEA is a safe and effective treatment option that offers:

• Multiple mechanisms of action of azelaic acid (AzA)
• Continuous improvement in lesions and erythema
• 36-week maintenance data
• Additional patient benefits

FINACEA is also the #1 prescribed topical rosacea treatment among dermatology healthcare professionals.

FINACEA Plus™

FINACEA Plus™ packages together FINACEA with 3 oz bottles of CeraVe® Moisturizing Lotion and CeraVe® Hydrating Cleanser. Dermatology healthcare professionals agree on the importance of skin care in the successful management of mild to moderate rosacea. Rosacea patients’ skin, especially when treated with topical medications, needs to be gently cleansed and moisturized, and FINACEA Plus™ can help them do that easily and effectively. Offering these three components in one convenient package provides patients an easy way to help manage their symptoms and take good care of their skin. CeraVe® Hydrating Cleanser provides gentle, effective cleansing while it restores and enhances the skin barrier. CeraVe® Moisturizing Lotion is uniquely formulated to increase the skin’s ability to attract, hold and distribute moisture.

Intendis also offers SKIN SAVVY, a patient program for support and compliance, through the web site myfinacea.com. SKIN SAVVY offers patients up to $30 instant savings on FINACEA, and up to $10 savings on skin care products, as well as expert tips, testimonials and before & after photos to help educate patients.

Finacea is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

Finacea is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. Finacea is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety – Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion, these patients should be monitored for early signs of hypopigmentation.

Please see full Prescribing Information for FINACEA by clicking here.

To access the Intendis video library, click here.